Introduction
============

*Enterobacteriaceae* are the most common cause of healthcare associated infections, and beta-lactams are among the most used antibiotics in clinical practice for treatment of these infections \[[@r1],[@r2]\]. During the last decades, *Enterobacteriaceae* with decreased susceptibility to beta-lactams have been increasingly reported worldwide, causing major problems \[[@r3]-[@r8]\].

The most important resistance mechanism to beta-lactams in *Enterobacteriaceae* is the production of beta-lactamases, and the most challenging enzymes of this family are the extended-spectrum beta-lactamases (ESBLs), the AmpC-type beta-lactamases (ACBLs), and the carbapenemases \[[@r9]-[@r12]\]. ESBLs are able to hydrolyse a wide range of beta-lactams, including penicillins, narrow- and extended-spectrum cephalosporins and monobactams, but not cephamycins and carbapenems. ESBLs are usually inhibited by conventional beta-lactamase inhibitors. CTX-M-type ESBLs, which emerged in the late 1980s, and demonstrated a high ability to disseminate in clinical settings, rapidly reaching a pandemic diffusion. Nowadays they are the most prevalent plasmid-encoded ESBLs overall \[[@r13],[@r14]\]. Acquired ACBLs can confer resistance to penicillins and to most cephalosporins (including cephamycins) but are poorly or not active against monobactams and the zwitterionic oxyimino-cephalosporins, such as cefepime and cefpirome, and the carbapenems. ACBLs are generally less prevalent than ESBLs in *Enterobacteriaceae* but are nonetheless important for their contribution to beta-lactam resistance, which can be extended also to carbapenems when ACBLs are overproduced in combination with an impermeability defect \[[@r10],[@r15],[@r16]\]. Carbapenemase production is the leading resistance mechanism to carbapenems in *Enterobacteriaceae*. Acquired carbapenemases of the KPC-, VIM-, NDM- and OXA-48-types are the most prevalent, although with a notable geographical variability \[[@r6],[@r17]-[@r20]\].

In Italy, the most recent data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) reported very high proportions of resistance to extended-spectrum cephalosporins among *Escherichia coli* (30.1%) and *Klebsiella pneumoniae* (55.9%), and of resistance to carbapenems among *K. pneumoniae* (33.5%) \[[@r21]\]. However, the EARS-NET data neither cover other enterobacterial species nor describe the resistance mechanisms.

This survey, promoted by the Committee for Study of Antibiotics (CoSA) of the Italian Society of Clinical Microbiologists (AMCLI), was carried out to provide an updated picture of the molecular epidemiology of ESBL- and carbapenemase-producing *Enterobacteriaceae* circulating in Italy and to investigate, for the first time, the presence of ACBL producers on a nationwide scale.

Methods
=======

Study design
------------

Fourteen clinical microbiology laboratories from 13 Italian cities participated in the study ([Figure 1](#f1){ref-type="fig"}).
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The laboratories were selected so as to provide a countrywide coverage by large laboratories associated with hospitals, representative of most Italian Regions. Twelve of the 14 laboratories had also been involved in the first Italian survey on carbapenemase-producing *Enterobacteriaceae*, carried out in 2011 \[[@r22]\]. The survey period was from 1 to 15 October 2013.

The laboratories consecutively collected all non-replicate (only first isolate from a patient included) clinical isolates of *E. coli*, *K. pneumoniae* and *Proteus mirabilis,* from any site of infection, showing a minimum inhibitory concentration (MIC) \> 1 mg/L for extended-spectrum cephalosporins (ESC) (cefotaxime and/or ceftriaxone and/or ceftazidime and/or cefepime), and/or for ertapenem. Participating laboratories determined MICs of ESC and ertapenem by the automated systems routinely used in the respective laboratory: either Vitek 2 (bioMérieux, Marcy l'Etoile, France) or BD Phoenix (Becton, Dickinson and Co., New Jersey, United States (US)). The collected isolates were sent to reference laboratories for confirmation of species identification and characterisation of the resistance mechanisms.

For each isolate, information on the type of clinical specimen and of patient (inpatient or outpatient) were provided. Isolates from patients from nursing homes or other long-term care facilities, and isolates from surveillance specimens, were excluded. Each laboratory also provided information on the total number of non-replicate clinical isolates of *Enterobacteriaceae* of the same species observed during the collection period from inpatients and outpatients.

Bacterial identification, antimicrobial susceptibility testing and phenotypic characterisation of resistance mechanisms
-----------------------------------------------------------------------------------------------------------------------

At the reference laboratories, identification of collected isolates was confirmed by MALDI-TOF mass spectrometry (Vitek MS, bioMérieux), and susceptibility to ESC (cefotaxime, ceftazidime, cefepime), carbapenems (ertapenem, imipenem, and meropenem), aztreonam, aminoglycosides (amikacin and gentamicin), ciprofloxacin, trimethoprim/sulfamethoxazole was determined by disc diffusion on Mueller-Hinton agar (for *P. mirabilis* imipenem was not tested) according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology \[[@r23]\]. MICs of tigecycline and colistin for carbapenemase producers were determined using reference broth microdilution \[[@r24]\] with custom lyophilised plates (TREK Diagnostic Systems, Cleveland, Ohio, US). All results were interpreted according to the EUCAST breakpoints \[[@r25]\]. ESBL production was investigated using the double disk method testing the synergistic activity between amoxicillin-clavulanate and cefotaxime, ceftazidime, cefepime, and aztreonam \[[@r26]\].

Molecular characterisation of resistance genes
----------------------------------------------

The presence of carbapenemase genes was investigated by multiplex real time-PCR (mRT-PCR) targeting *bla*~KPC-type,~*bla*~VIM-type~, *bla*~OXA-48-type~ and *bla*~NDM-type~ genes, using primers and conditions reported in [Table 1](#t1){ref-type="table"}. The presence of *bla*~CTX-M~ ESBL genes was investigated by a mRT-PCR, able to distinguish among different *bla*~CTX-M-type~ variants of groups 1, 2, 8/25 and 9, using primers and conditions reported in [Table 1](#t1){ref-type="table"}. The presence of ACBL genes was investigated by a multiplex PCR targeting genes encoding ACBLs, as described previously \[[@r27]\]. For *E. coli*, specific primers designed to distinguish between acquired and chromosomal ACBL genes were used \[[@r27]\]. The presence of *mcr-1*-like genes was investigated by a novel real time-PCR ([Table 1](#t1){ref-type="table"}).

###### Sequence of primers and probes used in nationwide surveillance survey of the molecular epidemiology of ESBL- and carbapenemase-producing *Enterobacteriaceae*, Italy, October 2013

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target                                Primer name                                Sequence (5'-3')^a^                    Reference     Positive control
  ------------------------------------- ------------------------------------------ -------------------------------------- ------------- -----------------------------------------------------------------------------------------------------------------------------------------
                                        OXA-48-like-rt-F                           GTAGCAAAGGAATGGCAAGAAA                 \[[@r44]\]    *Escherichia coli* ECBZ-1 (*bla*~OXA-48~) \[[@r45]\]\

  *bla* ~OXA-48-like~ genes             OXA-48-like-rt-R                           GATGCGGGTAAAAATGCTTG                                 

                                        OXA-48-like-rt-P                           HEX-CTCTGGAATGAGAATAAGCAGCAAGG-BHQ-1                 

  *bla* ~KPC~ genes                     KPC-rt-F                                   GATACCACGTTCCGTCTGG                    \[[@r46]\]    *Klebsiella pneumoniae* FIPP-1 (*bla*~KPC-3~) \[[@r47]\]\

  KPC-rt-R                              GCAGGTTCCGGTTTTGTCTC                                                                            

  KPC-rt-P                              FAM-AGCGGCAGCAGTTTGTTGATTG-BHQ-1                                                                

  *bla* ~VIM~ genes                     VIM-rt-F                                   TGGTCTCATTGTCCGTGATG                   \[[@r48]\]    *K. pneumoniae* VA-416/02 (*bla*~VIM-4~) \[[@r49]\]\

  VIM-rt-R                              CATGAAAGTGCGTGGAGA                                                                              

  VIM-rt-P                              ROX-AAGCAAATTGGACTTCCCGTAACGC-BHQ-2                                                             

  *bla* ~NDM~ genes                     blaNDM1_F                                  CGCAACACAGCCTGACTTT                    \[[@r50]\]    *E. coli* CVB-1 (*bla*~NDM-1~) \[[@r51]\]\

  blaNDM1_R                             TCGATCCCAACGGTGATATT                                                                            

  blaNDM1_P                             CY5-CAACTTTGGCCCGCTCAAGGTATTT-BHQ-3                                                             

  *bla* ~CTX-M~ group 1 genes           CTX-M-group-1_FW                           AAAAATCACTGCGCCAGTTC                   \[[@r52]\]    *E. coli* V460a (*bla*~CTX-M-15~), in-house control\

  CTX-M-group-1_REV                     AGCTTATTCATCGCCACGTT                                                                            

  CTX-M-group1-P                        HEX-TGGCGACGGCAACCGTCACGCTGTT-BHQ-1        This study                                           

  *bla* ~CTX-M~ group 2 genes\          CTX-M-group-2_FW                           CGACGCTACCCCTGCTATT                    \[[@r52]\]    *E. coli* C277a (*bla*~CTX-M-2~), in-house control\
  \                                                                                                                                     

  CTX-M-group-2_REV                     CCAGCGTCAGATTTTTCAGG                                                                            

  CTX-M-group2-P                        FAM-TATTGAGCGTGGGCTCGGTTCTGTCCAG-BHQ-1     This study                                           

  *bla* ~CTX-M~ group 8/25 genes        CTX-M-group-8/25\_ FW                      CGATACCACCACGCCATTAG                   This study    *E. coli* M26a (*bla*~CTX-M-8~), in-house control\

  CTX-M-group-8/25_REV                  AACCCACGATGTGGGTAGC                        \[[@r52]\]                                           

  CTX-M-group8/25-P                     CY5-CCTGAATGCTGGCAGCGCCGGTG-BHQ-3          This study                                           

  *bla* ~CTX~ *~-~* ~M~ group 9 genes   CTX-M-group-9_FW                           CAAAGAGAGTGCAACGGATG                   \[[@r52]\]    *E. coli* V404a (*bla*~CTX-M-14~) \[[@r53]\]\

  CTX-M-group-9_REV                     ATTGGAAAGCGTTCATCACC                                                                            

  CTX-M-group9-P                        ROX-CGTGCATTCCGCTGCTGCTGGGCA-BHQ-2         This study                                           

  All *bla*~CTX-M~ genes\               U-CTX-M- FW                                ATYRAYACMGCVGATAAYWCGCA                This study    *E. coli* V460a (*bla*~CTX-M-15~), *E. coli* C277a (*bla*~CTX-M-2~), *E. coli* M26a (*bla*~CTX-M-8~), *E. coli* V404a (*bla*~CTX-M-14~)
  \                                                                                                                                     

  U-CTX-M- REV                          CSGCAATSGGRTTRTAGTTAAC                     This study                                           

  U-CTX-M-P                             CY5.5-ATGTGCAGYACCAGTAARGTKATGGC-BHQ-3     This study                                           

  PhHV (internal control)               PhHV-267s                                  GGGCGAATCACAGATTGAATC                  \[[@r54]\]    PhHV DNA cloned in pGEM-T-easy *E. coli* DH5α\
                                                                                                                                        \

  PhHV-337as                            GCGGTTCCAAACGTACCAA                                                                             

  PhHV-305tq                            Cy5.5 -TTTTATGTGTCCGCCACCATCTGGATC-BHQ-3                                                        

  *mcr-1-*like genes\                   Mcr-1-rt-fwd                               ATCAGCCAAACCTATCCCATC                  This study\   *E. coli* FI-4531 (*mcr-1*) \[[@r55]\], *K. pneumoniae* KP-6884 (*mcr-1.2*) \[[@r33]\]\

  Mcr-1-rt-rev                          ACACAGGCTTTAGCACATAGC                                                                           

  Mcr-1-rt-p                            Cy5-GACAATCTCGGCTTTGTGCTGACGATC-BHQ-3                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ESBL: extended-spectrum beta-lactamases.

^a^ The amplification programme consisted of 35 two-step cycles of 15s at 95 °C and 60s at 60 °C.

Spectrophotometric assay for carbapenemase activity
---------------------------------------------------

In carbapenem non-susceptible isolates that tested negative for known carbapenemase genes, carbapenemase production was further investigated by measuring the imipenem-hydrolysing specific activity in bacterial crude extracts as described previously \[[@r28]\], using a Cary 100 UV-Vis spectrophotometer (Varian, Walnut Creek, California, US).

Statistical analysis
--------------------

Statistical evaluation of differences between resistance rates observed in this study and previous surveillance studies was carried out with the chi-squared test with Yates correction, using the Stata Statistical Software (release 13, College Station, Texas, US). Since the surveillance studies were overall similar by design but there were a few sampling differences, which could act as confounding factors, the tests were treated rather as exploratory analyses, which may indicate trends.

Results
=======

Prevalence of *Enterobacteriaceae* with resistance mechanisms to extended-spectrum cephalosporins and/or carbapenems
--------------------------------------------------------------------------------------------------------------------

During the study period, a total of 3,324 consecutive non-replicate clinical isolates of *Enterobacteriaceae* of the target species were isolated in the 14 laboratories participating in the survey, including 2,352 (70.7%) *E. coli*, 697 (21.0%) *K. pneumoniae,* and 275 (8.3%) *P. mirabilis*. Of these, 1,509 isolates (45.4%) were from inpatients and 1,815 (54.6%) from outpatients ([Table 2](#t2){ref-type="table"}).

###### Proportions of ESCR-carbaS and ESCR-carbaR of *Enterobacteriaceae* by species included and origin of isolate, nationwide surveillance survey, Italy, October 2013 (n=3,324 isolates)

  Species                   Isolates from inpatients   Isolates from outpatients   All isolates                                                                                                                                                                                                              
  ------------------------- -------------------------- --------------------------- ----------------- ------- ----------------- ------- ----------- ---------- ------- ----------------- ------- ----------------- ------- ----------- ---------- ------- ----------------- ------- ----------------- ------- ------
  **Total**                 **ESCR**                   **%**                       **ESCR‑carbaS**   **%**   **ESCR‑carbaR**   **%**   **Total**   **ESCR**   **%**   **ESCR‑carbaS**   **%**   **ESCR‑carbaR**   **%**   **Total**   **ESCR**   **%**   **ESCR‑carbaS**   **%**   **ESCR‑carbaR**   **%**   
  *Escherichia coli*        920                        230                         25.0              219     23.8              11      1.2         1,432      162     11.3              159     11.1              3       0.2         2,352      392     16.7              378     16.1              14      0.6
  *Klebsiella pneumoniae*   437                        159                         36.4              49      11.2              110     25.1        260        36      13.8              16      6.2               20      7.7         697        195     28.0              65      9.3               130     18.7
  *Proteus mirabilis*       152                        39                          25.7              39      25.7              0       NA          123        26      21.1              26      21.1              0       NA          275        65      23.6              65      23.6              0       NA
  Total target species      1,509                      428                         28.4              309     20.3              121     8.0         1,815      224     12.3              201     11.1              23      1.3         3,324      652     19.6              508     15.3              144     4.3

ESCR: non-susceptible to extended-spectrum cephalosporins; ESCR-carbaS: non-susceptible to extended-spectrum cephalosporins but susceptible to carbapenems; ESCR-carbaR: isolates non-susceptible to extended-spectrum cephalosporins and non-susceptible to carbapenems; NA: not applicable.

Overall, 508 isolates were confirmed to be non-susceptible to ESC but susceptible to carbapenems (ESCR-carbaS phenotype), and 144 isolates to be non-susceptible to both ESC and carbapenems (ESCR-carbaR). Isolates susceptible to ESC and non-susceptible to carbapenems were not detected.

The ESCR-carbaS phenotypes were contributed by all three species, with higher proportions among *P. mirabilis* (23.6%) and *E. coli* (16.1%) than among *K. pneumoniae* (9.3%), and with a higher proportion among isolates from inpatients (20.3%) but a remarkable proportion (11.1%) also among those from outpatients ([Table 2](#t2){ref-type="table"}).

The ESCR-carbaR phenotypes were mostly contributed by *K. pneumoniae*, with higher proportion among isolates from inpatients (25.1% of *K. pneumoniae*) but also a notable proportion among those from outpatients (7.7% of *K. pneumoniae*) ([Table 2](#t2){ref-type="table"}).

Considering the nature of resistant isolates, the majority of those from outpatients (n=224) were from urine (206/224, 91.9%), while those from inpatients (n=428) were from different specimens (urine: 239/428, 55.8%; blood: 55/428, 12.8%; respiratory tract samples: 54/428, 12.6%).

Beta-lactamase phenotypes and genotypes of the ESCR and carbapenem-resistant isolates
-------------------------------------------------------------------------------------

Of the ESCR-carbaS isolates, 460 (90.5%) were ESBL-positive and 384 of them (83.4%) carried a *bla*~CTX-M~ ESBL gene ([Figure 2](#f2){ref-type="fig"} and [Table 3](#t3){ref-type="table"}).
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###### Resistance mechanisms detected in the investigated phenotypic resistant isolates by species included, nationwide surveillance survey, Italy, October 2013 (n=652 isolates)

  Phenotypic resistance   Resistance mechanism         *Escherichia coli*   *Klebsiella pneumoniae*   *Proteus mirabilis*   Total                                      
  ----------------------- ---------------------------- -------------------- ------------------------- --------------------- ---------- --------- ----------- --------- ----------
                          **N**                        **%**                **n**                     **%**                 **n**      **%**     **n**       **%**     
  **Total**               **2,352**                    **100**              **697**                   **100**               **275**    **100**   **3,324**   **100**   
  Resistant               392                          16.7                 195                       28.0                  65         23.6      652         19.6      
  **ESCR-carbaS**         **Total**                    **378**              **96.4**                  **65**                **33.3**   **65**    **100.0**   **508**   **77.9**
  ESBL                    CTX-M-1                      264                  69.8                      50                    76.9       0         NA          314       61.8
  CTX-M-9                 61                           16.1                 0                         NA                    0          NA        61          12.0      
  CTX-M-1 + 9             8                            2.1                  1                         1.5                   0          NA        9           1.8       
  Other ESBL              28                           7.4                  9                         13.8                  39         60.0      76          15.0      
  ACBL                    CMY/LAT/ACT/MIR              12                   3.2                       0                     NA         24        36.9        36        7.1
  DHA                     0                            NA                   0                         NA                    1          1.5       1           0.2       
  Other                   Other resistance mechanism   5                    1.3                       5                     7.7        1         1.5         11        2.1
                                                                                                                                                                       
  **ESCR-carbaR**         **Total**                    **14**               **3.6**                   **130**               **66.7**   **0**     **0.0**     **144**   **22.1**
  CARBA                   KPC                          2                    14.3                      108                   83.2       0         NA          110       76.4
  VIM                     1                            7.1                  2                         1.5                   0          NA        3           2.1       
  OXA-48                  2                            14.3                 3                         2.3                   0          NA        5           3.5       
  ESBL                    CTX-M-1                      4                    28.6                      9                     6.9        0         NA          13        9.0
  CTX-M-9                 3                            21.4                 0                         NA                    0          NA        3           2.1       
  CTX-M-1 + 9             0                            NA                   1                         0.8                   0          NA        1           0.7       
  ACBL                    CMY/LAT/ACT/MIR              2                    14.3                      0                     NA         0         NA          2         1.4
  DHA                     0                            NA                   2                         1.5                   0          NA        2           1.4       
  Other                   Other resistance mechanism   0                    NA                        5                     3.8        0         NA          5         3.5
                                                                                                                                                                       
  **Total**               **Total**                    **392**              **100**                   **195**               **100**    **65**    **100**     **652**   **100**
  CARBA                   KPC                          2                    0.5                       108                   55.4       0         NA          110       16.9
  VIM                     1                            0.3                  2                         1.0                   0          NA        3           0.5       
  OXA-48                  2                            0.5                  3                         1.5                   0          NA        5           0.8       
  ESBL                    CTX-M-1                      268                  68.4                      59                    30.3       0         NA          327       50.2
  CTX-M-9                 64                           16.3                 0                         NA                    0          NA        64          9.8       
  CTX-M-1 + 9             8                            2.0                  2                         1.0                   0          NA        10          1.5       
  ACBL                    CMY/LAT/ACT/MIR              14                   3.6                       0                     NA         24        36.9        38        5.8
  DHA                     0                            NA                   2                         1.0                   1          1.5       3           0.5       
  Other                   Other resistance mechanism   33                   8.4                       19                    9.7        40        61.5        92        14.1

ACBL: acquired class C beta-lactamase-producing; CARBA: carbapenemase-producing; CTX-M-1: CTX-M group 1 producers; CTX-M-9: CTX-M group 9 producers; CTX-M-1+9: CTX-M group 1 and group 9 producers; ESBL: extended-spectrum beta-lactamase-producing; ESCR-carbaR: non-susceptible to extended-spectrum cephalosporins and non-susceptible to carbapenems; ESCR-carbaS: non-susceptible to extended-spectrum cephalosporins but susceptible to carbapenems; NA: not applicable.

The proportion of *bla*~CTX-M~ genes was 92.2% among ESBL-positive *E. coli* and 84.7% among ESBL-positive *K. pneumoniae*, while such genes were never detected among ESBL-positive isolates of *P. mirabilis* ([Figure 2](#f2){ref-type="fig"}). Among CTX-M-positive isolates, most carried *bla*~CTX-M~ genes of group 1 (81.5%), while a minority carried *bla*~CTX-M~ genes of group 9 (16,0%) and a small proportion carried *bla*~CTX-M~ genes of both CTX-M groups (2.5%) ([Table 3](#t3){ref-type="table"}). CTX-M-positive isolates were detected from all centers ([Figure 1](#f1){ref-type="fig"}).

Comparison of these data with results from the earlier Italian nationwide survey on producing ESBL-producing *Enterobacteriaceae*, carried out in 2003 \[[@r29]\], revealed a notable increase in the proportion of ESBL-producing isolates (from 6.4% to 14.4%; p \< 0.001, considering the three target species). Among outpatients, the proportion of ESBL producers increased from 3.4% to 11.0% (p \< 0.001), and the increase was especially large among *E. coli* (from 1.9% to 10.9%; p \< 0.001).

The majority of the ESCR-carbaS isolates that were ESBL-negative were positive for an acquired ACBL gene (n = 37, 79%) which, in most cases, belonged to the CMY/LAT/ACT/MIR lineage. Most of the ACBL-positive isolates were *P. mirabilis* ([Figure 2](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}).

Concerning the ESCR-carbaR isolates, most (81.9%) were positive for carbapenemase genes, including *bla*~KPC~- (93.2%), *bla*~OXA-48~- (4.2%), and *bla*~VIM~-type (2.6%) carbapenemase genes. The majority of carbapenemase-producers were *K. pneumoniae*, while only five *E. coli* produced a carbapenemase ([Figure 2](#f2){ref-type="fig"}). Interestingly, some KPC-positive *K. pneumoniae* (KPC-KP) (6.5%) and most OXA-48-positive isolates also harbored a *bla*~CTX-M~ gene ([Table 3](#t3){ref-type="table"}). The 26 ESCR-carbaR isolates that tested negative for carbapenemase genes were confirmed to be carbapenemase non-producers by spectrophotometric assay. Most of these isolates carried *bla*~CTX-M~ genes (65.3%) while a minority was positive for an ACBL gene (*bla*~DHA~ or *bla*~CMY/LAT/ACT/MIR~), suggesting that in these cases the carbapenem resistance mechanism was related with production of an ESBL or ACBL in combination with reduced permeability \[[@r30]\].

Comparison of these data with results from the first Italian nationwide survey on carbapenem-resistant *Enterobacteriaceae* (CRE), carried out in 2011 \[[@r22]\], revealed an increase in the proportion of carbapenem-resistant *K. pneumoniae* isolates (from 11.9% to 18.7%) although the difference was not statistically significant (p = 0.5). KPC-KP remained the major contributors (83.1% of carbapenem-resistant *K. pneumoniae* in 2013 *vs*. 87.2% in 2011). Among outpatients, the proportion of KPC-KP increased from 2.2% in 2011 to 4.6% (p \< 0.05).

A detailed distribution of the resistance genes in the Italy is reported in [Figure 2](#f2){ref-type="fig"}, and the distribution by species and type of patients is reported in [Table 2](#t2){ref-type="table"}.

Antimicrobial susceptibility
----------------------------

All ESBL-producing isolates that were carbapenemase-negative remained susceptible to imipenem and meropenem, while ertapenem susceptibility was 98.1% among *E. coli* and 82.2% among *K. pneumoniae* ([Table 4](#t4){ref-type="table"}).

###### Antimicrobial susceptibility testing results for the investigated isolates, nationwide surveillance survey, Italy, October 2013 (n=652 isolates)

  ------------- --------------------------- ------- -----------------
  **Species**   **Phenotypic resistance**   **n**   Susceptible (%)
  ------------- --------------------------- ------- -----------------

  AK                        GM     CIP     CAZ    CTX    FEP    IMI    MEM    ERT     AZT     TRIM/SUL   COL^a^   TIG^a^                   
  ------------------------- ------ ------- ------ ------ ------ ------ ------ ------- ------- ---------- -------- -------- ------- ------- ----
  *Escherichia coli*        ESBL   368     94.8   61.7   9.8    10.6   0.8    14.9    100.0   100.0      98.1     6.3      43.8    NA      NA
  CARBA                     5      80.0    60.0   20.0   20.0   0.0    20.0   80.0    60.0    0.0        20.0     40.0     100.0   100.0   
  Others                    19     100.0   89.5   52.6   0.0    0.0    94.7   100.0   100.0   89.5       5.3      42.1     NA      NA      
  Total                     392    94.9    63.0   12.0   10.2   0.8    18.9   99.7    99.5    96.4       6.4      43.6     NA      NA      
  *Klebsiella pneumoniae*   ESBL   73      91.8   39.7   21.9   4.1    6.8    6.8     100.0   100.0      82.2     8.2      26.0    NA      NA
  CARBA                     113    16.8    48.7   0.9    0.0    0.0    0.0    3.5     3.5     0.0        0.0      25.7     61.9    94.4    
  Others                    9      66.7    88.9   44.4   0.0    66.7   77.8   100.0   88.9    55.6       77.8     55.6     NA      NA      
  Total                     195    47.2    47.2   10.8   1.5    5.6    6.2    44.1    43.6    33.3       6.7      27.2     NA      NA      
  *Proteus mirabilis*       ESBL   39      92.3   0.0    30.8   43.6   7.7    61.5    NA      100.0      100.0    87.2     25.6    NA      NA
  CARBA                     0      NA      NA     NA     NA     NA     NA     NA      NA      NA         NA       NA       NA      NA      
  Others                    26     96.2    57.7   7.7    0.0    0.0    88.5   NA      100.0   100.0      100.0    7.7      NA      NA      
  Total                     65     93.8    23.1   21.5   26.2   4.6    72.3   NA      100.0   100.0      92.3     18.5     NA      NA      

AK: amikacin; AZT: aztreonam; CARBA: carbapenemase production; CAZ: ceftazidime; CIP: ciprofloxacin; COL: colistin ; CTX: ceftriaxone; ERT: ertapenem; ESBL: extended spectrum beta-lactamase production; FEP: cefepime; GM: gentamicin; IMI: imipenem; MEM: meropenem; NA: not applicable; TIG: tigecycline; TRIM/SUL: trimethoprim/sulfamethoxazole .

^a^ COL and TIG were tested only for carbapenemase producers.

Among the carbapenemase producers, all were non-susceptible to ertapenem, while most carbapenemase-producing *E. coli* were susceptible to imipenem and meropenem (80.0% and 60.0%, respectively). Carbapenemase-producing *K. pneumoniae* were more susceptible to gentamicin than to amikacin (48.7% *vs*. 16.8%). Broth microdilution assays, carried out with the 113 carbapenemase-producing *K. pneumoniae*, revealed that 61.7% and 94.4% were susceptible to colistin and tigecycline, respectively, while all five carbapenemase-producing *E. coli* were susceptible to both drugs ([Table 4](#t4){ref-type="table"}). These results were overall similar to those reported from the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) survey in 2015 \[[@r31]\], and underscore the remarkable rate of colistin resistance among carbapenemase-producing *K. pneumoniae* circulating in Italy. No significant differences in susceptibility to these two drugs were detected among inpatients and outpatients (data not shown).

Screening for *mcr-1*-like genes in colistin-resistant isolates
---------------------------------------------------------------

The 43 colistin-resistant carbapenemase-positive *K. pneumoniae* isolates were screened for the presence of *mcr-1*-like genes, encoding transferable colistin resistance \[[@r32],[@r33]\]. All the tested isolates yielded negative results, revealing that colistin resistance was caused by different mechanisms.

Discussion
==========

This study provides an updated picture of the prevalence, distribution, beta-lactamase profiles and susceptibilities of ESBL-, carbapenemase- and ACBL-producing *E. coli*, *K. pneumoniae* and *P. mirabilis* circulating in Italy.

Compared with the earlier Italian nationwide survey on ESBL-producing *Enterobacteriaceae*, carried out in 2003 \[[@r29]\], the proportion of ESBL-producing isolates (considering the three target species) showed a notable increase, especially among outpatients and among *E. coli*. At the level of resistance mechanisms, this epidemiological evolution was associated with a remarkable increase in the prevalence of CTX-M-type enzymes, which, in 2013, represented by far the most common type of ESBL in *E. coli* and in *K. pneumoniae*. Interestingly, despite their ability to spread, the genes encoding these resistance mechanisms have not disseminated in *P. mirabilis*, where the ESCR phenotype was found to be relatively common (23.6% of isolates) but due to other mechanisms, i. e. ESBLs other than CTX-M-type or ACBLs, mostly of the CMY/LAT/ACT/MIR lineage. A similar epidemiological evolution was observed in other European Countries including Belgium (with 77% vs 46% of CTX-M-positive isolates, among ESBL-producing *E. coli*, in 2008 vs 2006) \[[@r34]\], Spain (with 72% vs 52% of CTX-M- positive isolates among ESBL-producing *E. coli* in 2006 vs 2000) \[[@r35]\].

Concerning carbapenem resistance, a notable increase was observed among *K. pneumoniae* in comparison with data from the first Italian nationwide survey on CRE, carried out in 2011 \[[@r22]\], with KPC-KP remaining the major contributors of CRE endemicity in Italy and other types of carbapenemases remaining uncommon. These findings underscore the ability of carbapenemase-producing *Enterobacteriaceae* (CPE) to rapidly disseminate and establish conditions of high-level endemicity, and the notion that CPE are associated with a heightened epidemiological risk and deserve special attention, as readily acknowledged by the European Centre for Disease Prevention and Control (ECDC) \[[@r36]\]. Indeed, the data from the EARS-NET surveillance system indicate that there is an overall increasing spread of CRE in some European countries \[[@r21]\], and results from the EuSCAPE project have shown that some regions are experiencing a worrisome prevalence of CPE per 10,000 hospital admissions, ranging from four to six for Italy, Greece and Spain \[[@r37]\].

Interestingly, KPC-KP isolates were also found from outpatients, at a rate that was approximately double compared with that found in the 2011 survey (4.6% vs 2.2%) \[[@r22]\]. Since a significant proportion of these outpatients could have been recently hospitalised or otherwise have had contact with healthcare services, this figure may not reflect accurately the prevalence of KPC-KP in the community, in Italy. However, this finding points to an increasing dissemination of CPE also outside the hospital setting, likely reflecting the ability of KPC-KP to establish persistent intestinal colonisation even after hospital discharge \[[@r38],[@r39]\]. It might herald a possible dissemination in the community like the one previously witnessed with CTX-M-producing *E. coli* \[[@r40]\]. Indeed, recent reports from the US and Spain have described the emergence of CPE infections also in the community, underscoring this possibility \[[@r41],[@r42]\]. Such a scenario should be avoided, and suitable infection control measures should be enforced to address this phenomenon in settings of high CRE endemicity like Italy and some other European countries \[[@r37]\].

In this grim scenario, the good news was that (i) overall carbapenem susceptibility was retained by *P. mirabilis*, with no carbapenemase-positive isolates detected in this species despite the high endemicity of CPE; and that (ii) no *mcr-1*-like transferable colistin resistance genes were detected among the colistin-resistant CPE isolates, suggesting that this worrisome resistance mechanism remains uncommon among colistin-resistant CPE circulating in Italy.

Updated molecular surveillance data on resistance genes to beta-lactams are of increasing importance due to the introduction on the market of new antibiotics for resistant Gram-negatives that are based on new beta-lactamase inhibitors (e. g. avibactam), which will be useful for treatment of infections caused by ESBL and carbapenemase producers \[[@r43]\]. The new inhibitors, however, are not active against all beta-lactamases e. g. avibactam is able to inhibit class A but not class B beta-lactamases. Thus the possibility of using these new drugs will depend on the specific mechanism of resistance, and rapid testing for these resistance mechanisms will become an essential step in antibiotic stewardship programs. In this perspective, this survey underscores the major role of beta-lactamase genes as resistance determinants in *Enterobacteriaceae* in the Italian epidemiological setting, and provides relevant information for the selection of the most suitable diagnostic strategies based on molecular detection of beta-lactam resistance mechanisms. A limitation of this study is that, due to the study design, laboratory-based surveillance, information about risk factors for developing antibiotic resistance was not available. Future studies are warranted to investigate these aspects, which are relevant to understand the reasons for the epidemiological differences observed in different European countries and to contextualise infection control policies.

Results of this work were partially presented at the 25th ECCMID in Copenhagen (2015) as an oral presentation, O143.
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